---
title: "AtriCure Q2 net income turns to USD 8.96 million; revenue rises 12.8% to USD 153.6 million year over year"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293959967.md"
description: "AtriCure reported Q2 net income of USD 8.96 million, reversing a loss, with revenue rising 12.8% year-over-year to USD 153.6 million. Operating income turned positive at USD 9.7 million, and gross margin expanded to 77.2%. Pain management revenue surged 27.8%, while minimally invasive ablation declined 23.1%. The company received EU MDR CE marks for AtriClip FLEX-Mini and PRO-Mini in April, expecting European launches later this year."
datetime: "2026-07-27T17:08:31.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293959967.md)
  - [en](https://longbridge.com/en/news/293959967.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293959967.md)
---

# AtriCure Q2 net income turns to USD 8.96 million; revenue rises 12.8% to USD 153.6 million year over year

-   AtriCure posted Q2 revenue of USD 153.6 million, up 12.8% year over year, swinging to net income of USD 9 million. \* Operating income turned positive at USD 9.7 million; gross margin widened 2.69 percentage points to 77.2%. \* Pain management revenue climbed 27.8% to USD 27.1 million, while minimally invasive ablation fell 23.1% to USD 6 million. \* Appendage management revenue rose 14.4% to USD 51.6 million; open ablation increased 12.1% to USD 40.9 million. \* Received EU MDR CE mark for AtriClip FLEX-Mini and AtriClip PRO-Mini in April; expects to launch both in Europe later this year. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AtriCure Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001323885-26-000035), on July 27, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [ATRC.US](https://longbridge.com/en/quote/ATRC.US.md)

## Related News & Research

- [AtriCure Chief Scientific Officer Vinayak Doraiswamy disposes of $233,280 in common shares](https://longbridge.com/en/news/294417197.md)
- [Board Member At AtriCure Exercises Options Worth $491K](https://longbridge.com/en/news/294530665.md)
- [AtriCure to join Needham Virtual MedTech & Diagnostics investor conference](https://longbridge.com/en/news/293928171.md)
- [Atricure Still Faces Broad, Evolving Risks Despite No Material Changes in 2025 10-K Disclosures](https://longbridge.com/en/news/294017350.md)
- [Why Bloom Energy shares are tanking ahead of earnings](https://longbridge.com/en/news/294089106.md)